UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Study of Epratuzumab in Systemic Lupus Erythematosus
Phase 3
Withdrawn
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00382837
The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
Phase 4
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2008-03-10
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 184
- Registration Number
- NCT00381758
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
Phase 3
Completed
- Conditions
- DermatitisEczema
- Interventions
- Drug: Placebo-CetirizineDrug: Placebo-LevocetirizineDrug: Standard topical steroid (1% hydrocortisone) ointment
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 466
- Registration Number
- NCT00375713
A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR
Phase 3
Completed
- Conditions
- Epilepsy
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 158
- Registration Number
- NCT00368069
- Locations
- 🇧🇷
N01235 1007, Curitiba, Brazil
🇫🇮N01235 2002, Turku, Finland
🇮🇳N01235 3010, Chennai, India
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
Phase 3
Completed
- Conditions
- Unverricht-Lundborg Disease
- Interventions
- Drug: BRV 25 mgDrug: BRV 2.5 mgOther: PlaceboDrug: BRV 50 mg
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 56
- Registration Number
- NCT00368251
- Locations
- 🇫🇷
121, Lille, France
🇫🇷122, Bron, France
🇮🇱170, Tel Aviv, Israel
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
Phase 3
Withdrawn
- Conditions
- Crohn's Disease
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00358683
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
Phase 3
Completed
- Conditions
- Unverricht-Lundborg Disease
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 50
- Registration Number
- NCT00357669
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease
Phase 3
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Certolizumab pegol
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 106
- Registration Number
- NCT00356408
Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
Phase 3
Withdrawn
- Conditions
- Crohn Disease
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00354367
Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease
Phase 3
Terminated
- Conditions
- Crohn's Disease
- Interventions
- Biological: certolizumab pegol 400 mgOther: Placebo
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 174
- Registration Number
- NCT00349752
© Copyright 2025. All Rights Reserved by MedPath